Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.24 USD
+0.06 (5.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.23 -0.01 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.24 USD
+0.06 (5.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.23 -0.01 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
by Zacks Equity Research
Nektar Therapeutics (NKTR) needs Investors to pay close attention to the stock based on moves in the options market lately.
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
by Zacks Equity Research
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
by Zacks Equity Research
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
Nektar Therapeutics (NKTR) Up 57.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca Stock Rising in '17: What's Working in its Favor?
by Zacks Equity Research
Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
by Zacks Equity Research
Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.
Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.
Shire Gets FDA Approval for Label Expansion of Adynovate
by Zacks Equity Research
Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age
3 Biotech Stocks to Turn the Tide This Earnings Season
by Zacks Equity Research
The biotech sector has strong fundamentals, and healthy product pipelines.